angiotensin ii has been researched along with bardoxolone methyl in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhindi, R; Birgisdottir, AB; Bubb, KJ; Figtree, GA; Hansen, T; Karimi Galougahi, K; Kok, C; Meyer, C; Rasko, NB; Reisman, SA; Ritchie, R; Tang, O; Ward, K | 1 |
1 other study(ies) available for angiotensin ii and bardoxolone methyl
| Article | Year |
|---|---|
The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling.
Topics: Angiotensin II; Animals; Atrial Natriuretic Factor; Cells, Cultured; Disease Models, Animal; Fibronectins; Glutaredoxins; Heart; Humans; Male; Myocardial Infarction; NF-E2-Related Factor 2; Nitric Oxide Synthase Type III; Oleanolic Acid; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Signal Transduction; Ventricular Remodeling | 2017 |